Defining clinical risk: How do we tailor therapy (SABCS 2022)
Tamoxifen and aromatase inhibitors have been proven to reduce the risk of recurrence by about 30-50%, and their use should be expected to decrease risk of recurrence...And for those with clear margins, there was excellent (100%) agreement between the Nomogram and the refined Oncotype DCIS score. Given the need for cost-based value in health care, and given the cost-free availability of a validated predictive online DCIS nomogram, rigorous evaluation of predictive accuracy and proof of significant added clinical benefit should be performed and made available before any new expensive commercially available test is adopted for clinical use.